Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation + SHR-1701 + Famitinib in Advanced Intrahepatic Cholangiocarcinoma
NCT07147088Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa and famitinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 24 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
retlirafusp alfafamitinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07147088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07147088.